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Abstract 
 
Charged particle beam therapy has been used for its twofold advantageous behavior: 
offering high precision to the target volume and minimum doses to organs at risk and 
normal function tissue. Treatment outcome of pancreatic patients is compromised by 
dose limits of the gastrointestinal tract and dose escalation is critical due to inter-
fractional uncertainties. 
The aim of this work (at University Clinic of Heidelberg) was to assess tissue 
variations by water equivalent path-length (WEPL) changes and find the dosimetric 
criteria where corrective actions should be taken i.e. re-optimization of the treatment 
plan. 
Two types of analysis were performed by comparing planning-CT and rigidly co-
registered weekly-CTs for 11 patients: A) Dose Forward calculation performed using a 
research TPS TRiP98, from the treatment plan clinically applied to the patients. The 
dose evaluation parameters were V95%PTV, V95%CTV and Gamma-index criteria. B) 
WEPL maps were generated using the MeVisLab framework to quantify densities 
variation as a percentage of voxels for the defined range of tissue variation (±3mm 
H2O). 
Both Gamma-index and V95%PTV showed tendency to increase or decrease with 
WEPL variations by strong correlation of 0.73 and 0.6, respectively. A criterion of 
WEPL as 56% interprets more than 3% variations in V95%PTV and Gamma passing 
rate lower than 96.5% (with distance to agreement as 3mm and dose difference of 
3%).  
The studied method proved to be a prediction tool for physicians in decision making 
for treatment plan re-optimization need due to inter-fractional density variation, with 
less computational time and without contouring structures. 
 
Keywords: Charged particle therapy, plan adaptation, pancreas, water equivalent 
path-length 
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Chapter 1 
Introduction  
1.1 Motivation 
According to the recent study proposed by World Health Organization (WHO) 
[1], pancreatic cancer is the twelfth most common cancer in the world and due to its 
silent behavior usually diagnosed at advanced stages. The new cases diagnosed with 
pancreatic cancer reached to 338,000 per year and about 277,000 people die each 
year worldwide due to this disease [2] which sets it to seventh position for being most 
common cause of death from cancer in the world. Although pancreatic cancer 
incidence is infrequent, it has the worst survival and mortality rate of all twenty-two 
common cancers.  
Pancreatic cancer is considered as one of the most challenging tumors in the 
field of oncology due to its decreased prognosis rate. Patients diagnosed with 
localized pancreatic tumor qualify for resection but their survival rate remained poor 
due to the high rate of relapse [3]. For locally advanced unresectable pancreatic 
cancer (LAPC), radiotherapeutic approaches are frequently employed which includes 
intensity modulated radiation therapy (IMRT) and image guided radiation therapy 
(IGRT) for conformal absorbed dose distribution and minimum absorbed dose to 
normal tissues. 
It turned out that the use of modern X-rays therapies for pancreatic cancer is 
limited when dose escalation is desirable and this limitation is mainly due to the 
surrounding radiosensitive normal organs such as duodenum, stomach, jejunum, liver, 
and kidneys [4]. Alternatively, charged particles therapy, either proton or carbon, has 
been considered as a promising alternative due to its explicit advantage; delivering 
significant dose to the target/tumor while simultaneously minimizing dose to normal 
tissues [5]. Many researchers have investigated on the aforementioned benefit of 
proton therapy by comparison with modern X-rays therapies and argued that 
treatment of pancreatic cancer with proton therapy demonstrates significant reduced 
absorbed dose to the normal tissues [6,7,8]. Similarly, Japanese studies concluded 
increased local control and overall survival rate for pancreatic cancers treated with 
carbon ion therapy [9]. 
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To date, most of the particle therapy facilities have been using broad beams 
and patient-specific absorbers to conform the dose to the target volume – passive 
beam delivery system. Moreover, an alternative method has been developed for 
treatment delivery with high precision – active beam scanning system. This technique 
allows a pencil beam to raster scan the entire target volume with modulated energy of 
the beam. At Heidelberg Ion-Beam Therapy Center (HIT), all the pancreatic cancer 
patients have been treated with this technique either with proton or carbon ion since 
2014.  
It has been observed [53] that the benefit of scanning systems is usually 
compromised by the treatment of moving tumors such as pancreatic tumor. Being an 
abdominal organ, pancreas experiences internal organ motion and respiratory induced 
motion which causes strong inhomogeneous dose distribution. Furthermore, daily 
setup errors, tumor shrinkage and bowel motion results in beam range variation. In 
general, the inevitable inter-fractional motion manifests itself in beam undershoot or 
overshoot. The above mentioned uncertainties explains explicit requirement of 
treatment plan adaptation for pancreatic patients treated with charged particle therapy. 
1.2 Scope of this Work 
Given the fact that organ motion influences the treatment outcome, this might 
requires re-optimization of the treatment plan. This situation become more critical for 
patients with abdominal cancer such as pancreatic patients, who are more susceptible 
to internal organ motion due to extreme bowel movement, weight loss, tumor 
shrinkage and respiration.  
Daily plan adaptation is an advance approach but not as feasible for ion-beam 
therapy as it is for photon therapy because of the plan complexity and time taken for 
re-planning. In practical scenario when patients are imaged before treatment delivery, 
it is difficult to predict how the bowel movement and weight loss will affect the dose 
distribution and assess the necessity of re-planning.  
In this thesis, the intention was to develop criteria (considering the dosimetric 
tolerances) where corrective action should be taken, therefore, re-optimization of the 
treatment plan, with less computational work and time consumption.   
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Chapter 2 
Background and Fundamentals 
2.1 Background 
In the community of radiotherapy researches are striving consistently to 
improve the quality of treatments and investigate new ways of treating cancer. One 
such way is to treat cancer with charged particles therapy and its use has been 
hypothesized to yield improved treatment as compared to photon and electron 
therapies. The use of charged particles, either proton or carbon, have been shown to 
be beneficial for pancreatic cancer patients [6,7,8,9]. This chapter presents some 
basics of particle physics required for the good understanding of this work.  
2.1.1 History to Present 
The well-known beneﬁt of charged particle therapy, the characteristic inverted 
depth dose proﬁle with a high local absorbed dose in a well-deﬁned depth (Bragg 
peak), was first suggested by Robert Wilson in 1946 [10]. The substantial biological 
and physical advantage of protons was investigated from treating the first human 
patient with protons beam in the mid-1950s at the University of California Lawrence 
Berkeley Laboratory [11].  
Until 1990 proton facilities were dedicated for research purposes but in the 
same year the first clinical based proton therapy facility for treatment of cancer 
patients was built at Loma Linda, USA [12]. In 1992 therapy with carbon ions was first 
implemented by Japanese in Chiba [13]. According to the Particle Therapy Co-
operative Group (PTCOG), there are 57 particle therapy facilities currently operating 
with a further 33 under construction in the world [14].  
2.2 Motivation for Particle Therapy 
The rationale for using charged particles in radiotherapy is mainly due to their 
beneficial physical characteristics in comparison to photons [15] and electrons. 
Charged particles possess finite range in tissue which helps in dose sparing of critical 
structures distal to the target volume. The range of charged particle depends on the 
primary energy and the physical characteristics of target material. Although electrons 
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possess the same behavior but doesn’t represent a well defined Bragg Peak. This 
phenomenon aided particle therapy to increase the therapeutic window i.e. increasing 
the probability of tumor control over the damage of surrounding normal structures [16]. 
2.2.1 Energy Deposition and Absorbed Dose 
When a charged particle traverses through matter it ionizes atoms and 
deposits the energy along its path. The dose is a measure of the amount of energy 
from an ionizing radiation deposited in a mass of the material; absorbed dose defined 
by ICRU is [17]: 
  
  
  
 (2.1) 
Where ΔE is the absorbed energy to a mass element Δm and its SI unit is gray (Gy).  
The dose measurements which are usually performed with air filled ionization 
chamber should be converted to absorbed dose in water which can be calculated for a 
parallel beam, with particle fluence F, travelling through a thin layer of absorbing 
material with mass density ρ, as [59]: 
                
  
  
 
   
  
          
 
 
 
   
 
  (2.2) 
Where dE/dx is the energy loss of particles per unit path length i.e. stopping power or 
specific energy loss.  
2.2.2 Stopping Power 
Stopping power is the rate of energy loss per unit of path length by a charged 
particle of a specific kinetic energy in a medium of atomic number Z. When a deep 
located tumor needs to be irradiated, e.g. 30cm depth, it would require ion beam 
range corresponding to specific energy up to 220 MeV/u for protons and 430 MeV/u 
for carbon ions. Since the slowing down process, describing by the stopping power, is 
dominant by inelastic collision with the target electrons of the incident medium, it is 
expressed by the Bethe-Bloch formula [18]:  
 
  
  
 
        
 
    
   
    
 
   
             
 
  
 
 
 
  (2.3) 
Here Zp and Zt are the nuclear charges of the projectile and target, me and e are the 
mass and charge of the electrons respectively, <I> is the mean ionization energy of 
the target atom, C/Zt is a shell correction term and the density correction term is δ/2. 
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2.2.3 Bragg Peak and Spread Out Bragg Peak 
The entrance dose of the charged particles is comparatively lower than for 
photons and demonstrates dose escalation in distal region followed by a very steep 
dose fall-off to almost no dose. Charged particles ionization density increases with 
increased depth which results in deposition of majority of the energy at a certain depth 
in a material. This narrow region of increased ionization density at the end of the 
charged particles range is known as Bragg peak. In figure 2.1 the behavior of charged 
particles, proton and carbon, is compared to the photon depth dose curve.  
 
Figure 2.1: Depth-dose profile of photon, proton and carbon ions 
The large mass difference of charged particle from atomic electrons makes 
them able to traverse in almost a straight line due to small deviations caused by 
atomic electrons. The depth of Bragg peak primarily depends on the initial energy of 
the particles, thus the charged particles beam has increased penetration depth as the 
incident beam energy increases.  
In order to cover the entire depth of the target volume with uniform absorbed 
dose, charged particles energy should be modulated to cover a spectrum of energies. 
For this purpose, a spread out Bragg peak (SOBP) can be achieved if multiple 
monoenergetic Bragg peaks are superimposed to yield conformed uniform dose to the 
target whilst sparing critical structures present distally. This phenomenal effect of 
SOBP results in high absorbed doses to the proximal area of the target in comparison 
to single Bragg peak, however, significantly less than in photon irradiation.   
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2.2.4 Range Straggling 
The path length is the distance that a charged particle travels before coming to 
rest.  The range is defined as the mean path length of a set of charged particles of the 
same incident initial energy.  Range straggling is responsible for the alteration in the 
individual path lengths and is due to the stochastic nature of the interactions that 
occur. The mean range R(E) can be related to the mass stopping power through 
equation 2.3 as [19]:  
       
   
  
 
   
 
    (2.4) 
The behavior of heavy ions has been demonstrated as in figure 2.2, where 
protons shows more range fluctuation as the energy increases, but much heavier ions 
like carbon have very less variation because heavy ions are very less scattered and 
travel almost on a straight line. 
 
Figure 2.2: Mean range of ions in water. The mean range of protons is higher than that of carbon at the 
same energy (shown by pink dashed lines) [19] 
2.2.5 Lateral Scattering 
When a charged particle traverses through an absorbing material it undergoes 
a lateral deflection while penetrating. This beam spread is primarily due to the 
Coulombs interactions with the target nuclei. The amount of deflection depends on the 
type of particle and its energy, for example carbon ions spreads less than protons 
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because they are heavier which makes carbon ions clinical superior for offering sharp 
dose gradients i.e. reduced doses to organ at risk (OAR) [20].  
2.2.6 Nuclear Fragmentation 
A certain fraction of protons have nuclear interactions in tissue, mainly with 16O 
(about 1% per cm of all protons in a beam) [21]. The nuclear interactions cause a 
decrease in primary proton fluence and lead to secondary particles absorbed dose 
such as neutron but the absorbed dose from these nuclear interactions is negligible in 
the Bragg peak. Instead, ions (heavier than protons) with energies of several 
hundreds of MeV/u possess significant contribution from nuclear interaction to 
absorbed dose and manifest itself as a dose tail at the distal end of the depth dose 
profile (for example carbon ions), see figure 2.1. 
2.2.7 Biological Effect 
In order to relate the biological effects from different types of radiation the 
relative biological effectiveness (RBE) is used. The RBE is dependent upon the 
absorbed dose, absorbed dose rate, fractionation and the irradiated tissue irrespective 
of the radiation type.  RBE is defined as the ratio of the absorbed dose from the 
reference radiation (photons) and the absorbed dose from the other radiation type 
producing the same biological effect. 
Protons possess slightly (10%) higher biological effects than that of photons. 
The generic approximation for the RBE value used for clinical proton beams is 1.1 [22] 
which means the protons will result in slightly higher damage to the tissues than the 
same dose of photon beam. Protons linear energy transfer (LET) increases with depth 
and so the RBE, however studies shows that RBE value varies between 1.1 (at the 
entrance of the beam) and 1.6 (at the distal edge of the Bragg peak) [23]. This 
variation could result in increase of protons effective range by few millimeters 
compared to the physical range. The aforesaid effect will have significant impact on 
treatments and organs at risk (OAR) close to the tumor although it is rarely taking into 
account at any proton therapy center.  
Carbon ions are superior to protons in terms of enhanced RBE which could 
also vary from 1 to 5 [24]. Similar to protons, high energy carbon beam demonstrate 
low RBE at the entrance of the beam and a high RBE in the target volume therefore 
the side effects to normal tissues are small whilst retaining maximum effect to target 
volume. Due to large variation in RBE of carbon ions, simple approximation is not 
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appropriate. A biological model, local effect model (LEM), has been developed to 
predict the RBE in mixed radiation field (combination of different energies of particles) 
[52]. Although, there are improved versions of LEM which have been established 
named LEM II and LEM III [25]. Other than LEM, there are different biological models 
also available to account with the biological effects for example the micro-dosimetric 
kinetic model (MKM) [54]. 
2.3 Charged particle Accelerators & Beam Transport System 
2.3.1 Production 
Protons can be accelerated to produce a beam of sufficient intensity and 
energy by two primary methods, through the use of either a cyclotron or a 
synchrotron.  The intensity should be high enough to deliver the treatment in a short 
period of time usually targeted around 2-3 minutes [26]. The proton energy should be 
in the range of 160 to 250 MeV which is necessary to deliver SOBP beams for a broad 
range of tumor depths. On the other hand, to accelerate carbon ions synchrotron is 
used. 
The cyclotron is a relatively simple particle accelerator, usually producing 
particles at a fixed energy, from the centre along a spiral path, which then has to be 
appropriately modified to make it suitable for treatment. Cyclotrons use two opposing 
evacuated dees separated by a gap in which an alternating electric field is applied 
[48]. Protons are accelerated in increasing orbits in response to the electric field each 
time they pass in-between the dees until the desired kinetic energy is achieved.  A 
static magnetic field oriented perpendicular to the orbit of the protons acts to keep the 
protons focused in orbit until exiting the cyclotron.  Energy degraders are used as 
needed to reduce the proton energy after the beam has exited the cyclotron.   
Synchrotrons, cyclic particle accelerator, can in principle produce beams of 
almost any energy up to the maximum, but because they are pulsed machines, it 
delivers the dose rather slowly, leading to reasonable longer treatment times and 
increased patient discomfort. A synchrotron requires the use of a “primary” linear 
accelerator to provide a source of 3 to 7 MeV protons to then further accelerate [26]. 
The protons are then accelerated in a ring of constant radius and kept focused in the 
desired orbit by the use of multiple bending magnets. The strength of the magnetic 
field and the radio frequency (RF) are increased as also the proton continuously gains 
in kinetic energy [26]. For this reason, a synchrotron can produce beams of variable 
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energy, consequently, and in contrast to a cyclotron, do not need energy degraders to 
produce a SOBP. 
2.3.2 Beam Delivery System 
The beam transport system is actually the connection part between the 
accelerators and treatment rooms. It is used to transfer the beam from the outlet of the 
accelerator to the entrance of the treatment rooms. Beam delivery systems are 
typically defined as either passive or active, depending on how the beam is conformed 
to the target. In the following both active and passive delivery systems are explained 
in detail. 
 
Figure 2.3: Illustration of a passive beam delivery system. The narrow, mono-energetic beam is broaden 
by a scattering system to match the required lateral dimensions. Lateral and longitudinal adaption to the 
tumor is performed by diﬀerent passive modulator devices. The distal edge of the tumor is conformed by 
an individually machined compensator which also results in unwanted dose to normal tissue (hatched 
area) [19]. 
Passive system 
Passive system provides conformity in the target by scattering and degrading 
the primary beam using various beam shaping devices as shown in figure 2.3. Beam 
modulation is required so as to achieve absorbed dose homogeneity in depth which 
could be accomplished by varying the thickness of absorber material through which 
the beam will travel therefore ridge filter or range modulator wheel are used [27]. 
Initially, a pair of scattering foil, help in increasing the width of the primary beam, then 
blocks and apertures are used to collimate the beam produced by the scatters, to the 
required target shape.  Finally, a customized patient specific compensator is used to 
shape the dose distribution to the distal edge of the tumor volume. This technique has 
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a limitation because it conforms the proximal edge of the target in a similar manner as 
it conforms the dose to the distal edge of the target volume which results in full dose 
to the normal tissues.     
Active system 
This system uses magnetic fields to scan the particle beam laterally across the 
target. Additionally also gives a capability to change the energy which allows 
conformality in three dimensions as shown in figure 2.4. There are two methods of 
beam scanning [28,29]: spot scanning and continuous scanning, for both the 
irradiation is delivered as a series of 2D layers. Spot scanning delivers the dose in 
finite steps, after delivering each beam it is switched off while the elements which 
steer the beam are reconfigured (changing beam position or energy) to deliver the 
dose to the next spot. According to ICRU, the spot positions should be separated by 
less than 80% of the beams full width half maximum (FWHM) to ensure homogeneous 
absorbed dose distribution [30]. The small separation among spots could reduce the 
sensitivity to fluctuations in the pencil beam position but increases the treatment time. 
The primary difference in spot and continuous scanning is that the beam remains on 
in continuous scanning when the position needs to be changed and each layer is 
irradiated, but it will be interrupted while changing the beam energy and turned on 
back for the next layer, this process will be repeated until the whole target has been 
fully irradiated. In figure 2.4 a raster scanning system has been demonstrated in which 
the beam dose is delivered in layers of same thickness and each layer will correspond 
to a specific energy (iso-energy slices, IES).  
 
Figure 2.4: Illustration of an intensity controlled magnetic scanning system in irradiating the target volume 
slice by slice with a moving pencil beam; suﬃcient overlapping is maintained to yield a homogeneous 
target absorbed dose in the longitudinal dimension (SOBP). [31]. 
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2.4 Treatment Planning 
In radiation therapy treatment planning is a major step which includes all the concepts 
explained above. This usually starts with acquiring a Computed Tomography (CT) for 
anatomical patient information; this has to be done without contrast agents (with 
different densities) to correctly calculate the range of the particles and the dose 
deposition in tissue (tumor and normal function tissue). Later other imaging modalities 
are used such as magnetic resonance imaging (MRI) and positron emission 
tomography (PET) to aid in better delineation of target and organs at risk (OAR) 
volumes segmentation.  
 
 
Figure 2.5: Representation of the ICRU volumes for 
treatment planning. CTV clinical target volume, GTV 
gross tumor volume, ITV internal target volume, PTV 
planning target volume [32] 
 
 
Gross Tumor volume: The GTV is the gross palpable or visible/demonstrable extent 
and location of malignant growth. 
Clinical Target Volume: The CTV is a tissue volume that contains a demonstrable 
GTV and/or subclinical microscopic malignant disease, which has to be eliminated. 
This volume thus has to be treated adequately in order to achieve the aim of therapy, 
cure or palliation. 
Internal Target Volume: This is the margin that must be added to the CTV to 
compensate for expected physiological movements and variations in size, shape, and 
position of the CTV during therapy. 
Planning Target Volume: The PTV, is a geometrical concept, and it is defined to 
select an appropriate beam size and beam arrangements, taking into consideration 
the net effect of all the possible geometrical variations, in order to ensure that the 
prescribed absorbed dose is actually in the CTV. 
Organs at risk: Organs at risk (OAR) are normal function tissues whose radiation 
sensitivity may significantly influence treatment planning and/or prescribed absorbed 
 12 
 
dose. Although the volume which includes margin around OAR that accounts for 
movement is called planning risk volume (PRV). 
After making a tridimensional (3D) model of the contoured structure the most 
suitable beam configuration has been defined (typically 1 or 2 beams in particles 
therapy) and dose distribution is adapted to the planned target/tumor volume; 
according to ICRU, 100% of the PTV volume should receive between 95% and 107% 
of the planned absorbed dose [33]. Beyond this step, treatment planning should 
incorporate the physical interactions of the particles in the tissue, algorithms and the 
biological model developed for absorbed dose calculation. This step requires inverse 
planning technique which optimizes the desired absorbed dose distribution and 
incorporates particle fluence while sparing OAR with proper dose constraints. 
However, a raster scanning system would require several scanning position to attain a 
homogeneous absorbed dose distribution for the target/tumor volume, in other words, 
for the application of Intensity Modulated Particle Therapy (IMPT) it incorporates 
superposition of the pencil beams with individual energy, position and particle number 
and yields a biologically effective dose distribution. On the other hand, the second 
approach is to optimize the weights on a field-by-field basis, that is, each field is 
optimized individually to deliver a fraction of the prescribed doses to the entire 
target/tumor volume. This method is called single-field optimization (SFO) [55]. 
Later the Treatment Planning System (TPS) performs the absorbed dose 
calculation based on the anatomical information from the patient CT imaging which 
contains information about electron density distribution (representing X-ray 
attenuation) in the human body given in Hounsfield (HU) values. The relationship of 
CT number and stopping power [56, 57] is a helpful measure to calculate the dose in a 
heterogeneous medium deposited by the Bragg peak.  In order to relate the travelling 
behavior of a charged particle with a CT voxel (representing HU), where voxel is a 3D 
form of pixel, corresponding to path length in water, a concept has been introduced as 
water equivalent path length (WEPL). For this purpose, Hounsfield units Look-Up 
Tables (HLUT) have been used in treatment plan optimization and absorbed dose 
determination. The HLUT is estimated by measuring HU values and particle ranges 
(WEPL) of tissue-equivalent materials using the stoichiometric method [58]. Lastly, 
absorbed dose optimization process assigns raster points to each layer with specific 
energy and spacing defined earlier to cover the target in water equivalent space. 
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2.5 The Heidelberg Ion-Beam Therapy Center 
At Heidelberg Ion Therapy (HIT) facility the first patient was treated in 2009 
with particle therapy. HIT is a part of the University clinic of Heidelberg based on the 
pilot project initiated at Helmholtz Center for Heavy Ion Research (GSI) [34]. This 
facility has three clinical beam-lines, two of them are horizontal and one with a gantry 
(figure 2.6) to allow different beam directions and was the worldwide first heavy ion 
gantry (isocentric) with beam scanning capabilities; however other two horizontal 
beams also provide beam scanning function. The ion energy ranges from 50 to 430 
MeV/u corresponds to ion penetration depths of 20 to 300 mm in water [35]. To date, 
HIT have been using protons and carbon ions for the clinical purpose although helium 
and oxygen ions are also available but limited to research purposes. At HIT facility, 
TPS Syngo (RT Planning by Siemens) have been used for clinical purpose however a 
research treatment planning system TRiP98 [36] is also available. Both incorporate 
the necessary requirements of a treatment planning software as explained in section 
2.4. Moreover a positron emission tomography and a CT machine (PET/CT) have 
been installed so as to evaluate the range of ions.  
 
Figure 2.6: Drawing of the heavy ion gantry at the HIT, 
including mechanics, beam line components and patient 
treatment room (MT Mechatronics) [35] 
 
 
2.6 Motion Impact on Treatment Delivery 
In the field of radiation therapy patient motion, either inter or intra-fractional, 
have been a major hurdle for the accurate delivery of treatment. Moreover the fact of 
using a beam scanning system turns motion issues more dominant. The anatomical 
site such as gastrointestinal (GI) system is susceptible to motion influences on the 
treatment outcome and workflow requires changes in treatment planning dosimetry 
and delivery. The inter-fractional motion affects the treatment in a matter of minutes to 
hours, thus requires interventions at the beginning of the treatment. The motion effect 
in the treatment of pancreatic patients is usually comprised of patient daily positioning 
and setup errors, internal organ motion such as tumor motion due to breathing effect 
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(intra-fractional motion) and changes in bowel movement (inter and intra-fractional), 
weight loss during the course of treatment and tumor shrinkage effect along the 
treatment [37].  
As far as patient positioning and setup errors are concerned, radiation therapy 
community have already investigated and established the state of the art 
immobilization systems and techniques which have been implemented in particle 
therapy as well. Therefore this study will concentrate on the other factors of inter-
fractional motion mentioned above assuming that patients were precisely localized 
and immobilized during treatment, although one has to realize there is always a 
possibility for further improvement.  
When we relate the effect of inter-fractional motion with particle therapy, it has 
been found that motion causes density heterogeneities which will not only affect the 
shape of the Bragg peak but also the position due to the range of particles, this effect 
can be seen in figure 2.7.  
 
Figure 2.7: The effect of density variation along the beam path has been demonstrated. (a) Proton tracks 
through a homogenous medium. (b) Similar tracks through a heterogeneous medium. (c) Same tracks 
through a shifted version of the density heterogeneity [38]. 
One of the common approaches for reducing the inter-fractional motion is 
adaptive therapy. For this purpose image guided techniques and re-optimization of 
dosimetry plans have been implemented to retain the dosimetric quality throughout 
the treatment course. As far as photons are concerned, plan adaptation strategy [39] 
is now being commonly used at some facilities but in particle therapy it is still a 
challenging step because of the time consumption due to complex treatment planning 
and delivery techniques. Even if the aforementioned factor has overcome, there is 
always the question ‘when is certainly needed plan adaptation?’ because there is no 
standard definition for such situations. 
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Chapter 3 
Plan Quality Assessment 
3.1 Introduction 
This chapter explains the dose calculations performed on a dataset of patients. 
It also provides an overview of treatment planning dosimetry performed on pancreatic 
patient at HIT and the use of research planning system for dose forward calculations 
on these patients. A complete detail has been shown about the patients included in 
this study regarding absorbed dose prescription, fractionation, field setups and chosen 
particle for therapy. Further dosimetric parameters have been defined for the 
evaluation of the treatment dosimetry plans and the results of those parameters have 
been discussed in detail. The impact of absorbed dose distributions on OARs has also 
been summarized in this chapter. 
3.2 Materials and methods 
3.2.1 Patient Cohort 
For this work (a retrospective study), eleven pancreatic patients were selected 
who were treated with scanned ion beam therapy including both carbon ions and 
protons at HIT facility from 2014 to 2016. Table 3.1 explains details of the patients 
regarding chosen particle for therapy, dose prescription, fractionation, field setups and 
number of weekly-CTs available. 
3.2.2 Patient Workflow 
In the following, patient workflow has been described for the patients included in this 
study: 
Patients positioning and immobilization: Patients were positioned prone on 
vacuum mattress, hands were raised above their head and feet were resting on a 
bolster, shown in figure 3.1. The skin marks were placed which will help in daily 
positioning.  
Planning CT: For treatment planning, a free-breathing CT (Somatom Sensation Open 
CT scanner by Siemens) covering from diaphragm to iliac crest was acquired without 
contrast. Additionally, a CT with contrast agent and a 4DCT (based on respiratory 
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gating) are acquired in combination with CT to allow a better definition of the target 
volume and organs at risk. 
 
Figure 3.1: Patient positioning and immobilization for pancreatic treatment patients of this study 
Particle selection: Ten patients were treated for proton beams and only one patient 
with carbon ion beam, refer to Table 3.1. The selection criteria for proton over carbon 
ions and vice versa depend on physician’s practice.  
 
Patient Particle Dose (GyE)/fr No. of Weekly-CT 
No. of Fields and Setup 
(refer to figure 3.2) 
A Proton 1.8 / 25 5 2; Setup A 
B Proton 1.8 / 25 3 2; Setup A 
C Proton 1.8 / 25 3 3; Setup B 
D Proton 1.8 / 25 3 2; Setup A 
E Proton 1.8 / 25 3 2; Setup A 
F Proton 2 / 27 3 2; Setup A 
G Proton 1.8 / 25 3 2; Setup A 
H Proton 1.8 / 25 4 2; Setup A 
I Carbon 4 / 12 1 2; Setup A 
J Proton 1.8 / 25 5 2; Setup A 
K Proton 1.8 / 25 6 2; Setup C 
Table 3.1: Details of all the patients included in this study: particle selection, absorbed dose per fraction, 
number of weekly-CTs and treatment field configuration 
Treatment planning: All treatment plans were planned using TPS Syngo (RT 
Planning by Siemens), refer to section 2.4, using IMPT technique with iso-energy slice 
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(IES) of 3 mm and full width at half maximum (FWHM) of 10 mm for carbon ions, 3mm 
IES and 8 mm FWHM for protons. Dosimetry plans were optimized to cover the PTV 
with homogenous absorbed dose and simultaneously reducing the dose to the OARs 
to the clinical dose constraints. 
Field setup: In this study nine out of eleven patients had two posterior oblique fields 
(figure 3.2 setup A). The other two patients were planned with different geometries to 
reduce the dose in kidney and bowel OAR, hence one patient had right lateral and a 
posterior field (setup C) and one patient had two posterior oblique and a posterior field 
(setup B). The field setups for all the patients are described in Table 3.1 and shown in 
figure 3.2.  
 
Figure 3.2: Different field configuration used for the patients included in this study 
Dose prescription: For proton beam therapy, the typical dose regime used is 45 GyE 
in 25 fractions and 9 GyE in 5 fractions for a boost volume. This research work does 
not include the evaluation for the boost plan. For the patients included in this work, 
dose fractionation is summarized in Table 3.1. In the following all the dose values are 
given in GyE referring to weighted dose by relative biological effects (RBE) for protons 
and carbon ions. 
Patient position verification and treatment delivery: Before treatment delivery, 
patients are aligned using skin marks with laser and this setup is verified with 
orthogonal X-ray images acquired in the treatment room related with the (initial) 
planning-CT. Those images then are compared with Digitally Reconstructed 
Radiograph (DRR) for bony anatomy alignment and corrective measures taken as per 
need. After alignment adjustments, treatment is delivered according to the dosimetry 
plan. 
Weekly-CT: Each patient was scheduled for follow-up weekly-CTs however resulting 
in a different number of weekly-CTs for the whole treatment course; this detail is 
described in table 3.1. These CTs were performed using the PET/CT scanner 
(Siemens Biograph mCT, Siemens Molecular Imaging). In this study, the total number 
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of weekly-CTs acquired was 39 from 11 patients. The weekly-CTs were performed in 
accordance with the planning-CT, same patient positioning, free-breathing and without 
contrast. 
3.2.3 Image Registration 
Weekly-CTs acquired from each patient were registered with their respective 
planning-CT using 3D slicer platform software [40]. The rigid registration approach 
was used as it aligns images of the same subject acquired at different times in the 
clinical routine. Rigid registration gives 6 degree of freedom (DOF) which consists of 3 
translations and 3 rotations. The transformation mapping was done by keeping 
Planning-CT image as fixed image (reference) and weekly-CT image as moving 
image (target). The landmarks matching criteria included bones i.e. vertebral column 
and ball-bearing (BB) fiducials which were placed on patient skin for alignment at the 
time of scanning.   
3.2.4 Contoured Volumes 
In the following, the contoured volumes have described which were used for planning-
CT and weekly-CT plan doses evaluation: 
Target volume: For forward absorbed dose calculation the target volumes including 
GTV, CTV, ITV and PTV were transferred from the TPS Syngo (RT planning by 
Siemens) and applied to the planning-CT and respective weekly-CTs.  
Group A Group B Analyzed OARs 
Redrawn OARs used for 
weekly-CTs 
OARs used for weekly-CTs 
as used in planning-CT 
Spinal Cord, Left 
kidney, Right 
Kidney, Bowel  
Patient A Patient F 
Patient B Patient I 
Patient C Patient J 
Patient D Patient K 
Patient E   
Patient G   
Patient H   
Table 3.2: Details about contoured OARs for weekly-CTs 
 19 
 
Organs at Risk (OAR): Table 3.2 contains details about the contoured OARs for 
weekly-CT of all the patients. There were seven out of eleven patients who had new 
OAR drawn per weekly-CT which was useful for dose evaluation. For other four 
patients same OARs were used for the weekly-CTs as were drawn for planning-CT. In 
this study the dose evaluation of OAR was limited to only 3 organs: spinal cord, both 
kidneys and bowel, as expressed in Table 3.2. 
3.2.5 Absorbed Dose Calculation 
As stated in the section 2.4, planning-CTs were optimized and calculated on a 
commercial TPS. For this purpose, the dose distribution of weekly-CTs and planning-
CTs were forward calculated using TRiP98. Thus the dose distributions correspond to 
the same clinically applied to patients with the aim to cover the CTV with the 
prescription absorbed dose.  
Plan assessment parameter: The dose evaluation parameters were set as volume of 
CTV received 95% dose (V95%CTV), volume of PTV received 95% of dose (V95%PTV), 
PTV maximum dose, PTV minimum dose (Dmin) and PTV mean dose to (Dmean).  
For dose plan comparison purpose gamma-index has been used since it is 
more sensitive to high and low dose gradients regardless of the contoured volumes. It 
is a single metric for dose maps that combines features of both dose difference (DD) 
and distance to agreement (DTA), see equation (3.1). It quantitatively compare both 
the planning-CT (      ) and weekly-CT       dose distributions in terms of dose values 
and their positions, respectively with the acceptance criteria in this research work of 
3% dose difference and 3mm distance to agreement [41].  
             
             
 
    
 
                  
 
   
 (3.1) 
For the results, a gamma distribution and gamma passing rate was computed using 
Plastimatch open-source software [42]. This was a helpful tool for the assessment of 
high dose region of OARs and low dose regions within target volume.  
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3.3 Results – Absorbed Dose Distribution 
3.3.1 Plan Quality Parameters 
In the following, dosimetric parameters were evaluated from the dose 
distributions of planning-CT and weekly-CTs. For comparison V95%PTV variation was 
calculated for all the weekly-CTs to their respective planning-CT as shown in figure 
3.3. In figure 3.4 the mean and standard deviation for V95%PTV has been 
demonstrated for all patients.  
 
Figure 3.3: V95%PTV variation along the weekly-CTs for all the 11 patients in reference to planning-CT  
 
Figure 3.4: Mean and standard deviation of V95%PTV variation over weekly-CTs represented individually 
for all the 11 patients 
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It was observed that only one patient had almost zero variation of PTV 
coverage for all the weekly-CTs. There were 6 out of 11 patients who had V95%PTV 
variation within 3% along the treatment. For worst case the variation was up to 7% 
which was observed even for first weekly-CT. For some cases maximum variation was 
observed for first weekly CT and minimum variation for last weekly-CT, for example 
patient E and patient F in figure 3.3. On the other hand, there were few cases where 
aforesaid effect was reversed for example patient B and patient D. The complete 
result can be seen in appendix, table A.1(a). 
The deviation of the maximum dose within the PTV was evaluated for all the 
patients and demonstrated in figure 3.5. 
 
Figure 3. 5: PTV Maximum dose along the weekly-CTs for all the 11 patients in reference to planning-CT 
(since patients have different dose per fraction, refer to table 3.1) 
The dose per fraction is different for each patient for that reason refers to table 
3.1 for the details. For most of the patients, PTV maximum dose remained consistent 
along the weekly-CTs while comparing with their respective planning-CT. The 
maximum variation was of 0.5GyE and minimum was of 0.02GyE. The major deviation 
was observed for those patients who had worst V95%PTV for the weekly-CTs, for 
example patient F and patient K in figure 3.3 and figure 3.4. However patient G 
represented high deviation even with minimum V95%PTV variation as shown in figure 
3.3 and figure 3.5. In figure 3.6 the mean and standard deviation for the maximum 
dose of PTV has been demonstrated for all patients. The complete result can be seen 
in appendix, table A.1(a). 
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Figure 3. 6: Mean and standard deviation of PTV maximum dose represented individually for all the 11 
patients. Note patient I refers to the carbon-ion patient, with dose per fraction 4GyE. 
The deviation of Dmin within the PTV was evaluated for all the patients and 
demonstrated in figure 3.7. 
 
Figure 3.7: PTV Dmin along the weekly-CTs for all 11 the patients in reference to planning-CT (since 
patients have different dose per fraction reader is referred to table 3.1) 
There were 4 out of 11 patients who had Dmin lower than 0.5GyE for all the 
CTs. There were considerable deviations of Dmin for all the patients along the 
treatment course. For example, patient B had increased V95%PTV variation as shown 
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in figure 3.3 and also represents Dmin almost zero for all the weekly-CTs. While 
comparing with plan Dmin to the weekly-CTs, the maximum variation for Dmin was of 
0.6GyE and minimum variation was of 0.01GyE. In figure 3.8 the mean and standard 
deviation for the PTV Dmin has been demonstrated for all patients. The complete result 
can be seen in appendix, table A.1(a). 
 
Figure 3.8:  Mean and standard deviation of PTV Dmin represented individually for all the 11 patients 
The deviation of Dmean within the PTV was evaluated for all the 11 patients and 
demonstrated in figure 3.9. For all the patients PTV Dmean was fairly consistent in 
comparison with Dmin and PTV maximum dose.   
 
Figure 3.9: PTV Dmean along the weekly-CTs for all the 11 patients in reference to planning-CT (since 
patients have different dose per fraction reader is referred to table 3.1) 
 24 
 
For comparison, V95%CTV variation was calculated for all the weekly-CTs to 
their respective planning-CT as shown in figure 3.10.  
 
Figure 3.10: V95%CTV variation along the weekly-CTs for all the 11 patients in reference to planning-CT 
It turned out that majority of the patients had relatively stable dose conformity 
within CTV than PTV as shown in figure 3.3. There were 9 out of 11 patients who had 
V95%CTV variation within 3% for all the weekly-CTs. Although patient K showed worst 
variation up to 13.6% for first weekly-CT and 0.4% variation for last weekly-CT. In 
figure 3.11 the mean and standard deviation for V95%CTV has been demonstrated for 
all the eleven patients. The complete result can be seen in appendix, table A.1 (b). 
 
Figure 3.11: Mean and standard deviation of V95%CTV variation represented individually for all the 11 
patients 
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3.3.2 Gamma-Index 
Gamma analysis was performed to compare planning dose distribution with 
their respective weekly-CTs as shown in figure 3.12. In figure 3.13 the mean and 
standard deviation for gamma passing rate has been demonstrated for all the eleven 
patients. The complete result can be seen in appendix, table A.1 (b). 
 
Figure 3.12: Gamma passing rate along the weekly-CTs for all the 11 patients in reference to planning-
CT 
 
Figure 3.13: Mean and standard deviation of gamma passing rate represented individually for all the 11 
patients 
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There were 5 out of 11 patients who had gamma passing rate of more than 
97% for all the weekly-CTs. The lowest passing rate was 91.3% and the highest was 
99.7%. We can relate the worst cases to their dosimetric parameters, for example 
patient J shows major variation of gamma passing rate because this patient had 
gradual decrease of Dmin in PTV (shown in figure 3.7) from 1 GyE to almost 0 GyE as 
the number of weekly-CT increased (see similar trend shown in figure 3.12). 
3.3.3 OAR Dose Evaluation 
As mentioned in section 3.2.4 this study includes only 3 OARs for dose 
evaluation (bowel, kidneys and spinal cord). Table 3.3 shows the parameters under 
evaluation and the results by taking average and standard deviation over all the 
eleven patients and weekly-CTs. The complete result can be seen in appendix, table 
A.2. 
OAR Parameter 
Plan (mean 
and std. dev) 
Weekly-CTs 
(mean and 
std. dev) 
Range 
Plan Weekly-CTs 
      
Bowel V20 (%) 16.3 ± 5.64 16.8 ± 5.64 [9.3; 24.3] [3; 24.4] 
 
V80 (%) 7.26 ± 3.77 8.11 ± 4.46 [1.67; 13.7] [1.14; 17] 
      
Right Kidney V40 (%) 19.57 ± 10.76 19.7 ± 7.85 [11.1; 46.8] [7.8; 37.2] 
Left Kidney V40 (%) 19.27 ± 12.56 23.2 ± 11.7 [0; 41.6] [0; 40.7] 
      
Spinal Cord 
Dmax 
(GyE) 
37.2 ± 3.71 37.3 ± 3.71 [32.4; 45.36] [32.4; 45.36] 
       
Table 3.3: Comparison of dose volume data of the OARs acquired from dose volume histogram (DVH) 
analyzed for this study. (Average and standard deviation was taken over all the 11 patients and all the 
weekly-CTs) 
Bowel movements have been a major concern in inter-fractional motion for 
most of the patient in this study. It turned out that the air in bowel along the beam path 
resulted in over-dosage of the bowel lying distally to the target volume. Figure 3.14 
demonstrates variation of the amount of volume receiving 20% of the prescribed dose, 
for half of the patients it remained consist or slightly lower for the weekly-CTs in 
comparison to the plan. However figure 3.15 showed high increase in the amount of 
volume receiving 80% of the prescribed dose, for example patient B the amount of 
bowel increased gradually from 9% for the CT of the week 1 up to 17% for the week 3. 
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This concludes that the aforementioned effect of bowel movements result in high 
dosage to increased amount of volume, although the dose to the target doesn’t reflect 
this variation. 
 
Figure 3.14: Bowel V20 evaluation representing variation along the weekly-CTs in reference to planning-
CT for all the 11 patients 
 
Figure 3.15: Bowel V80 evaluation representing variation along the weekly-CTs in reference to planning-
CT for all the 11 patients 
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As far as kidneys and spinal cord are concerned, inter-fractional motion does 
not appear to be highly effective on these OARs. The spinal cord Dmax along the 
weekly-CTs remained persistent with the planning-CT for the entire set of patients with 
the exception of patient F whose Dmax increased by 1%. Similarly, for kidneys, 
receiving 40% of the dose, remained under (or consistent) with planning-CT for all the 
eleven patients. 
All the result from this chapter can be seen in appendix table A.1 (a), table A.1 
(b) and table A.2. Moreover, the absorbed dose distribution images for all the 11 
patients can be seen in appendix, figure A.3. 
3.4 Summary  
The results from this chapter shown that the inter-fractional motion effects the 
absorbed dose distribution; however the degree of effect depends on the amount of 
tissue variations caused by inter-fractional motion along the beam path. In terms of 
target volume the dose conformity for CTV was less affected by the inter-fractional 
motion in comparison to PTV. It turned out that the air in bowel causes the range 
uncertainty of the beam resulting in over dosage of the bowel as well.  
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Chapter 4 
WEPL Assessment 
4.1 Introduction 
This chapter explains a detailed study about water equivalent path length 
variation (∆WEPL) caused by inter-fractional motion. In the previous chapter the effect 
of inter-fractional motion on the absorbed dose distribution had been studied and the 
contributing factors were discussed while this chapter will essentially aid in quantifying 
the effect of those factors by calculating WEPL. In the following an introduction of the 
software used has been given for WEPL calculation and its features have been 
explained. Moreover it explains the detail about the parameters used for evaluation 
purposes and the types of analysis performed. Lastly, results are presented. 
4.2 Method and Materials 
For the WEPL analysis the same dataset of patients was utilized as in the plan 
quality assessment (chapter 3). The analysis was performed on the MeVisLab 
framework [40], in a module that was developed at the HIT facility, as part of the 
SPARTA project funded by the German Research Foundation. Analysis was done by 
comparing planning-CT to weekly-CTs. For the stated purpose, all the patient images 
were rigidly registered in the same manner as it was done for dose forward calculation 
(section 3.2.3) by implementing the image registration parameters acquired from 3D 
Slicer into MeVisLab module to depict the same patient alignment. The contoured 
structures set were transferred to MeVislab from Syngo TPS (RT planning by 
Siemens) for analysis.   
4.2.1 MeVisLab- Module Workflow  
After the image registration process, the software generates WEPL maps for 
one treatment field at a single time by defining isocenter (gantry and couch angles) as 
shown in figure 4.1, considering the HLUT table from the selected CT imaging 
protocol. Once the field is defined, the volume of interest (VOI) (explained in section 
4.4.3) need to be set as a reference target for which the analysis should be performed 
and also the type of analysis, which will be explained in section 4.2.3. The software 
generates the accumulated WEPL (accWEPL) in the individual beam’s eye view 
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(BEV), by rotation of the CT according with the given gantry and couch angles. The 
accWEPL incorporate all the tissue variations for planning-CT and weekly-CT along 
the beam path for the selected VOI projected in BEV, as shown in figure 4.2. 
Additionally, the module also generates an accWEPL difference map by subtracting 
both the individual maps as shown in figure 4.3.  
 
Figure 4.1: MeVisLab interface for defining isocenter, gantry and couch angle 
 
Figure 4.2: Individual BEV showing accWEPL for planning-CT (left) and weekly-CT (right); 
 example of patient E for weekly-CT 1 
 
Figure 4. 3: accWEPL difference map of the planning-CT and weekly-CT for the same patient as shown 
in figure 4.2 
4.2.2 Evaluation Features and Tools 
For this study, the evaluation was done using the accWEPL difference map of 
tissue variation among planning-CT and weekly-CT. Most of the time in clinical 
practice 3 mm-water variation (in absorbed dose distribution) is considered as a 
general rule, thus for computing accWEPL difference map, a minimum range of tissue 
variation (in other words, acceptable tissue variations) was set as ±3 mm-water as 
shown in figure 4.4.  
For analysis and visualization purposes accWEPL difference maps were set to 
show only points outside the range of ±3mm. At this point, the software shows a 
difference map as in figure 4.3 where different colors represent variations in 
millimeters as it was set in scalar bar at the bottom of the map, however the black 
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area within the map represents points within the range of ±3mm. Simultaneously a 
histogram is generated depicting the number of voxels lying inside and outside the 
range set as shown in figure 4.5; this histogram gives a percentage of voxels lying 
inside the defined range and is denoted as PVin. If PVin is higher that means less 
tissue variations represent more than ±3mm variation and if PVin is low then higher 
possibility of having tissue variations larger than ±3mm.  
 
Figure 4.4: The range setting option to visualize the accWEPL difference map with only the point which 
lies outside range set. 
 
Figure 4.5: Histogram corresponding to accWEPL difference map, showing number of voxels within and 
outside the range; example of patient J for field 1 
Furthermore, the software also gives an option of visualizing per beam 
experienced variation on the accWEPL maps, which helps in knowing the exact 
amount of tissue variation in millimeters as ‘current value’ for a specific voxel. Also the 
variation along the beam path can be seen in CT-value (HU) as a CT profile for that 
specific beam as shown in figure 4.6, 4.7, 4.8 and 4.9.  
 
Figure 4.6: Example of patient B showing tissue variation along the beam path for same slice in planning-
CT and weekly-CT. (Red arrow= active field direction, grey arrow= inactive field direction during the 
WEPL calculation) 
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Figure 4.7: Example of patient B; variation of density given by the CT-value along the same beam path as 
shown in figure4.6 (Aqua blue=planning CT, magenta= weekly CT) 
 
Figure 4.8: Example of patient B; same point indication on accWEPL difference map as shown in figure 
4.6 and 4.7 
 
Figure 4. 9: Showing the current value from accWEPL map for the specific point shown in figure 4.8 
4.2.3 Evaluation Parameter 
Volume of interest (VOI)  
From the contoured structure set, CTV was selected as a reference volume, 
additionally a margin of 1mm in x, y directions (anterior-posterior and left-right) and 
3mm in (superior-inferior) z direction was introduced as shown in figure 4.10. This 
entire volume including CTV and the margins was denoted as volume of interest 
(VOI). Although, above mentioned margins does not have any clinical or dosimetric 
relevance.  
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Figure 4.10: Illustration of volume of interest used for WEPL map generation 
Normalized PVin (PVnorm) 
As explained in section 4.2.1, MeVisLab module computes a PVin value per 
field from the accWEPL difference maps. Since the patients in this study had at least 2 
fields and at most 3 fields (refer to table 3.1) the PVin of each field was normalized by 
taking into account the respective field weight. This was done by averaging the field 
intensity i.e. number of particles (information acquired from raster scanning data of the 
initial treatment plan) from both fields. The resultant intensity was multiplied with PVin 
for each field, summed up and divided by the total number of particles of the complete 
plan. The end result was denoted as normalized PVin (PVnorm) which was calculated 
for each weekly-CT of all the patients.  
4.2.4 Types of Analysis 
To evaluate the tissue variation along the beam path, two analyses were 
performed for the VOI to generate accWEPL difference maps as shown in the figure 
4.11.  
 
Figure 4. 11: Illustration of types of analysis option used for calculating accWEPL. (a) Distal analysis, (b) 
Proximal analysis 
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Distal edge analysis: In this method, the WEPL is summed up along the beam path, 
starting from patient skin to the distal edge of the VOI in the BEV direction, see figure 
4.11 (a).  
Proximal edge analysis: In this method, the WEPL is summed up along the beam 
path, starting from patient skin to the proximal edge of the VOI in the BEV direction, 
see figure 4.11 (b). 
4.3 Results – WEPL maps 
4.3.1 Distal Analysis 
The results from distal analysis for all the eleven patients along the weekly-
CTs are demonstrated in figure 4.12. For 6 out of 11 patients who had better PVnorm 
(around 70% and above) for first weekly-CT, the PVnorm tend to decrease by 10% to 
23% for the second weekly-CT (Patients B,C,D,E,G,K). Only two patients 
demonstrated consistent behavior by having PVnorm within 3% along the weekly-CTs 
(Patient F, H). For patient J, large variations of up to 42% observed from weekly-CT2 
to CT5. In figure 4.13 the mean and standard deviation of PVnorm for distal analysis are 
demonstrated for all the eleven patients. The complete result of distal analysis can be 
seen in appendix, table A.1 (b). 
 
Figure 4.12: PVnorm variation from distal analysis along the weekly-CTs of all the 11 patients  
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Figure 4.13: Mean and standard deviation of PVnorm for distal analysis 
4.3.2 Proximal Analysis 
The results from proximal analysis for all the eleven patients are shown in the 
figure 4.14. The complete result of proximal analysis can be seen in appendix, table 
A.1 (b). 
 
Figure 4.14: PVnorm variation from proximal analysis along the weekly-CTs of all the patients 
 36 
 
Those 6 patients mentioned in distal analysis showed same pattern of 
decrement in PVnorm after the first weekly-CT. Patient F had a consistent behavior in 
distal analysis with PVnorm within 3% which changed to 6% in proximal analysis. For 
patient J and K, the variations became more prominent in comparison with distal 
analysis. In figure 4.15 the mean and standard deviation of PVnorm for proximal 
analysis are demonstrated for all the eleven patients. 
 
Figure 4.15: Mean and standard deviation of PVnorm for proximal analysis 
4.3.3 Comparison of Proximal and Distal Analysis 
As mentioned in section 4.2.3 the variation in accWEPL was assessed till the 
distal and proximal edge of the VOI, the comparison among distal and proximal 
analysis could actually depict that where majority of the density variation experienced 
by WEPL. For this purpose the total number of weekly-CTs from all the eleven 
patients, which makes 39 sets (see table 3.1) were considered as points separately 
for both distal and proximal analysis as shown in figure 4.16.  
It turned out that 26 out of 39 points were within 3% for both distal and 
proximal analysis which means variations in proximal analysis has 66% same amount 
of variations as in distal analysis. This results emphasis on the fact that in the majority 
of the cases increased density variation occurs outside the VOI and the target density 
changes are almost neglected. 
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Figure 4.16: Comparison of proximal and distal analysis; showing PVnorm variations for all the weekly-CTs 
included in this work 
4.4 Summary 
In this chapter the rationale was to quantify the effect of inter-fractional motion 
on WEPL. For this purpose a parameter was defined to evaluate the WEPL variations 
for each field and depict the combined effect. It turned out that the major variation in 
WEPL was primarily effected by the bowel movements (even with prone position) as 
we already concluded in Chapter 3. Secondly, WEPL variations were also affected by 
the change in amount of lung within the treatment field on daily basis and also due to 
the positioning error. The aforementioned effect was making major difference outside 
VOI, however, within VOI had slight effect.  
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Chapter 5 
WEPL Correlation & Criteria Definition 
5.1 Introduction 
In the previous chapter the goal was to quantify the density variation caused by 
inter-fractional motion by using WEPL. Also we have already discussed in chapter 3 
the effected dose distribution parameters. In this chapter, the correlation among 
dosimetric parameters and PVnorm calculated from accWEPL difference maps (which 
were evaluated in chapter 3 and chapter 4 respectively) has been observed. This was 
done by considering the dosimetric and WEPL variations on each weekly-CT from all 
the eleven patients. The goal was to find the best dosimetric parameter, which would 
strongly correlate with WEPL variation in a situation of high density variations. 
Furthermore, it was also the aim to obtain the criteria of WEPL variation which would 
help in predicting the resultant dosimetric effects on the dose distribution.  
5.2 Method and Materials 
This section explains about the parameters and method used to establish a dosimetric 
correlation, also describes the method for defining the threshold criteria. 
5.2.1 Correlation Parameters 
To evaluate the correlation among WEPL and dosimetric parameter, which were 
discussed in chapter 3 and 4, PVnorm was correlated with the variation of V95%CTV, 
variation of V95%PTV, gamma passing rate and for the most meaningful OARs doses 
(i.e, bowel). 
5.2.2 Correlation Method 
The Pearson correlation coefficient (denoted by r) was used to measure the strength 
of linear association among WEPL and dosimetric parameters. Additionally, a linear 
regression with the attempt to define the best linear fit is performed (straight line), 
which will help in showing how far the data points are from a linear fit. Also 95% 
confidence band has been drawn along the straight line.   
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5.2.3  Parameter Selection for Criteria Definition 
For the definition of the accWEPL variation criteria, those dosimetric parameters were 
considered which were moderately or strongly correlated with PVnorm. 
5.2.4 Action and Tolerance level definition 
By considering clinically reasonable variation in V95% and gamma passing rate, 
action and tolerance level were defined. For the variation in V95%, either for CTV or 
PTV, 2% and 3% variation was set as tolerance and action level respectively. 
Similarly, for gamma passing rate 97.5% and 96.5% were considered as tolerance 
and action level respectively. These values were used to compute the corresponding 
PVnorm by using the straight line equation from the correlation plots.  
5.3 Results 
5.3.1 CTV – V95% 
The correlation of V95%CTV variation and PVnorm of distal analysis has been 
demonstrated in figure 5.1.  
 
Figure 5.1: The correlation of V95%CTV variation and PVnorm for distal analysis, for all the 11 patients; 
where r=Pearson correlation coefficient, grey dashed line = linear regression (calculated from straight line 
equation shown as y), grey band= 95% confidence band 
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It was found that V95%CTV variation was not correlated, i.e. r of 0.047, with 
PVnorm and this was an expected result because if we observe the pattern of V95%CTV 
variations for all the patients in figure 3.10 and 3.11, there was only one patient who 
had high variation up to 13.6% and the majority of the patients remained within 3% 
along the weekly-CTs. 
. The correlation of V95%CTV variation and PVnorm for proximal analysis has 
been demonstrated in figure 5.2. There was a weak correlation among V95%CTV 
variation and PVnorm but slightly higher correlation, i.e. r of -0.21, in comparison to 
distal analysis. 
 
Figure 5.2: The correlation of V95%CTV variation and PVnorm for proximal analysis, for all the 11 patients; 
where r= Pearson correlation coefficient, grey dashed line = linear regression (calculated from straight 
line equation shown as y), grey band= 95% confidence band 
The combine assessment of distal and proximal analysis explained the reason 
for having a better correlation for proximal analysis than distal analysis, most of the 
time CTV remained homogenous with respect to density variation which justified the 
result in term of proximal vs. distal tissue variations in section 4.3.3. It was also 
observed that the high density variation within CTV was mainly due to the presence of 
a surgical clip which is also mobile due to internal organ motion; this fact will be 
explained further in the discussion section.  
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5.3.2 PTV - V95% 
The correlation of V95%PTV variation and PVnorm of distal and proximal analysis 
has been demonstrated in figure 5.3 and 5.4 respectively.  
 
Figure 5.3: The correlation of V95%PTV variation and PVnorm for distal analysis, for all the 11 patients; 
where r=Pearson correlation coefficient, grey dashed line = linear regression (calculated from straight line 
equation shown as y), grey band= 95% confidence band 
 
Figure 5.4: The correlation of V95%PTV variation and PVnorm for proximal analysis, for all the 11 patients; 
where r= Pearson correlation coefficient, grey dashed line = linear regression (calculated from straight 
line equation shown as y), grey band= 95% confidence band 
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In both the analyses, V95%PTV variation and PVnorm were strongly correlated 
with r of -0.6 due to the reason of having high variation in V95%PTV along the weekly-
CTs for majority of the patients as shown in figure 3.3 and 3.4. The reason for having 
better correlation of PVnorm with V95%PTV than V95%CTV is that PTV includes the 
margins of inter-fractional uncertainties thus PTV is more heterogeneous than CTV 
which results in inhomogeneous dose distribution. Although there were some outliers 
present which represented higher PVnorm also had high variation of V95%PTV. 
5.3.3 Gamma Passing Rate 
The correlation of gamma passing rate and PVnorm of distal and proximal 
analysis has been demonstrated in figure 5.5 and 5.6.  
 
Figure 5.5: The correlation of gamma passing rate and PVnorm for distal analysis, for all the 11 patients; 
where r=Pearson correlation coefficient, grey dashed line = linear regression (calculated from straight line 
equation shown as y), grey band= 95% confidence band 
A very strong correlation, i.e. r of 0.73 for distal and r of 0.7 for proximal 
analysis, has been observed among gamma passing rate and PVnorm since the 
variation in gamma passing rate fluctuated along the weekly-CTs for all the eleven 
patients as shown in figure 3.12 and 3.13. The reason for such strong correlation is 
that gamma index evaluates dose distributions of the absorbed dose plans 
irrespective of target volumes, which make it sensitive to high or low dose gradients, 
similarly accWEPL assess density variation along the beam path irrespective of target 
volume. The number of false positives (high PV norm but low gamma) and false 
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negatives (low PV norm but high gamma) has reduced in comparison to V95%PTV 
correlation because gamma index gives complete information of dose distribution (not 
only for PTV or CTV). 
 
Figure 5.6: The correlation of gamma passing rate and PVnorm for proximal analysis, for all the 11 
patients; where r = Pearson correlation coefficient, grey dashed line = line of best fit (calculated from 
straight line equation shown as y), grey band= 95% confidence band 
Since the dose distributions variation occurs more outside the target (that 
means in the normal tissues and OARs) than in the target volumes, this effect can be 
understood by an example as shown in figure 5.7 where a moderate correlation, i.e. r 
of -3.8, has been found among V20bowel and gamma passing rate. This also depicts 
that higher gamma passing rate give lower V20bowel and vice versa. 
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Figure 5.7: The correlation of Bowel V20 with gamma passing rate for all the 11 patients; where r = 
Pearson correlation coefficient, grey dashed line = line of best fit (calculated from straight line equation 
shown y), grey band= 95% confidence band 
5.4 Decision Criteria Definition (PVnorm Threshold) 
The assessment, evaluation and correlation of dosimetric parameters brought 
this study to a conclusive stage where a criterion of PVnorm can be predicted which 
could suggest the onward effects of dose distribution due to tissue variations. As 
explained in section 5.3.2 and 5.3.3 that both Gamma-index and V95%PTV showed 
tendency to increase or decrease with PVnorm by strong correlation of 0.73 and 0.6 
respectively.  
In a real clinical situation we cannot define a strict borderline for prediction that 
is why a general rule has been defined as a tolerance and action level demonstrated 
in table 5.1. The rationale of predicting such criteria is to use it as reference guide 
routinely in clinical patient scenarios; when patients has been imaged before the 
treatment delivery, a physicist would take 5 to 10 minutes for the calculation of WEPL 
maps and a physician will evaluate the resulting PVnorm to suggest if the patient should 
be treated or not. Conclusively it will help in plan adaptation.  
The tolerance level suggests that below PVnorm 70% there is a need to 
investigate further so as to be sure if patient should be treated or not, however, action 
level (obtained as a PVnorm of 56%) would strongly emphasis on plan re-optimization. 
One should realize that these defined criteria were defined for the specifications of this 
 46 
 
study, i.e., beam geometries, PTV and CTV margins, clinical protocol (that affects the 
GTV size) and dosimetric acceptance levels.  
 
Criteria PVnorm (%) 
V95%PTV 
Variation (%) 
Gamma passing rate 
(%) 
Tolerance Level 70 2 97.5 
Action Level 56 3 96.5 
Table 5.1: The criteria definition of PVnorm in terms of dosimetric action and tolerance levels 
5.4.1 Patient Examples  
In the following, patient examples have been explained which supports above mentioned 
criteria.  
1- Patient J 
The absorbed dose distribution for planning-CT has been shown in figure 5.8 
which represents a worst case in terms of target volume coverage to reduce higher 
doses to OARs; one can observe the amount of bowel close to CTV and inside PTV. 
The field configuration, dose per fraction and other specifications for this patient can 
be seen in table 3.1.  
 
Figure 5.8: Dose distribution of a planning-CT for Patient J. (Contoured OARs and target volumes: grey = 
spinal cord, lime = left kidney, mustard = right kidney, white = bowel, green = CTV, red = PTV) 
The dose volume histogram (DVH) of CTV in figure 5.9 has shown the 
variations along the weekly-CTs from planning-CT. The V95%CTV (where 95% dose is 
1.7GyE) of planning-CT was 56.4% and the maximum variation for the weekly-CTs 
was about 1.7% as we have already seen in figure 3.10 and 3.11 less variation for 
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V95%CTV along the weekly-CTs. Similarly, V95%PTV of the planning-CT was 49.5% 
and the maximum variation was up to 5% for the weekly-CTs as shown in figure 5.10.  
 
Figure 5.9: DVH of the CTV for the patient J including the evaluation of the planning-CT and 5 weekly-
CTs dose distributions; 95% of the prescription dose is 1.7GyE. 
 
Figure 5.10: DVH of PTV for patient J including planning-CT and 5 weekly-CTs; 95% dose=1.7GyE. (On 
the left is whole view and on the right is zoomed view) 
 
Figure 5.11 demonstrated that this patient attains the lowest PVnorm for weekly-
CT3 and CT5 which also correspond to lowest gamma passing rate as well as 
maximum PTV V95% variation. The reason for having low gamma passing rate was 
that the minimum dose within PTV reached gradually from 1GyE to almost zero along 
the weekly-CTs as shown in figure 3.7 although maximum dose stayed consistent as 
shown in figure 3.5. On the other hand, the minimum dose of weekly-CT4 was equal 
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to weekly-CT3 which gives a low gamma passing rate but demonstrated V95%PTV 
variation close to 1%. 
 
Figure 5.11: Bar graph for Patient J; lower PVnorm corresponds to lowest gamma passing rate and high 
variation in V95% PTV variation e.g. weekly-CT3 and CT5 
For detailed analysis of the above mentioned effects, each field was assessed 
for accWEPL difference to the planning-CT and found that for weekly-CT4 and CT5 
the peaks laid outside our defined minimum range ±3mm for tissue variation in both 
treatment fields as shown in figure 5.12 and 5.13. Also the maximum variation 
experienced by highest number of voxels was between -6mm to -9mm.   
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Figure 5.12: Histogram of accWEPL difference map for the Field 1; all the CTs of the Patient J. 
 
Figure 5.13: Histogram of accWEPL difference map for the Field 2; all the CTs of patient J. 
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Figure 5.14: Dose distribution of patient J weekly-CT1. This demonstrates how bowel movement effects 
the dose distribution. (blue = CTV and purple = PTV) 
It has been found that the major cause of very low PVnorm, i.e. strong WEPL 
variations, is the bowel movement for this patient as shown in figure 5.15. This 
situation effected weekly-CT3 and CT5 the most in terms of PVnorm however it was 
analyzed that the patient had extreme bowel changes along all the weekly-CTs. With 
this same effect on weekly-CT1 the PVnorm was very high and the reason for having 
high or low PVnorm is not only the amount of bowel movement but also how much area 
of a difference map is filled with lower variations; due to internal organ movement, 
setup and positioning error; which actually depicts the overall variations experienced 
in specific treatment field direction. As one can observe in figure 5.15 (a) there are a 
lot of points with different colors and (b) have most of the area in black meaning points 
within our range of ±3mm, this same explanation implies to figure 5.12 and 5.13.  
Regarding high variation of V95%PTV in weekly-CT1, was due to the dose 
limiting OARs invading PTV which result in compromised coverage of the target as 
shown in figure 5.14. Since both the treatment field weight was almost equal 
contributed in decreased dose conformity.  
All in All, patient J partially satisfies the defined criteria for all the weekly-CTs 
where weekly-CT2 represents a case which stays above the tolerance level. Weekly-
CT1 and CT4 will fall in the tolerance level because the PVnorm was almost 70% or 
lower. Although weekly-CT3 and CT5 stayed in action level, with PVnorm lower than 
56% representing more than 3% variation in V95%PTV and gamma passing rate as low 
as 96.5%.  
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Figure 5.15: Point analysis for Patient J (a) For Weekly-CT1, field 2, (b) For weekly-CT3, field 2. The 
bowel changes effect from planning-CT and weekly-CT can be observed in CT value (HU) and also in 
accWEPL difference map. In (a4, b4) the current value is the accWEPL value for the specific beam 
indicated by red arrow in (a1, a2, b1, b2). The important thing is the area of the difference map in (a4) 
filled with variations, most of the area is black which represents points within ±3mm. (Note: Apparently 
scan images are deformed because of the couch angle used and this is how software will look through 
that beam; the software doesn’t apply this deformation while calculating accWEPL) 
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2 - Patient F 
The dose distribution of patient F has been shown in figure 5.16, see table 3.1 
for further details about field configuration, dose per fraction and number of weekly-
CTs. This patient is one of those patients who had fluctuating variation of V95%CTV for 
all the weekly-CTs which was up to 2% as shown in figure 3.10. Although V95%PTV 
variation was up to 7% for first weekly-CT represented as a worst case and within 3% 
for the remaining weekly-CTs as shown in figure 3.3. The DVH of CTV and PTV in 
figure 5.17 shows the variation from planning-CT to weekly-CTs. The V95%CTV (where 
95% dose is 1.9GyE) for planning-CT was 98% and decreased to 95% for weekly-
CT1. The V95%PTV for planning-CT was almost 90% and decreased up to 83% for the 
weekly-CT1 as well. 
 
Figure 5.16: Dose distribution of a planning-CT for Patient F. (Contoured OARs and target volumes: grey 
= spinal cord, mustard = right kidney, white = bowel, aqua = liver, green = CTV, red = PTV) 
 
Figure 5.17: DVH of CTV (left side) and PTV (right side) for patient F including planning-CT and 3 
weekly-CTs; where 95% dose is 1.9GyE 
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This patient represents lowest and consistent value for PVnorm along the 
weekly-CTs, see figure 5.18. The weekly-CT1 represents more than 7% variation in 
PTV V95% and gamma passing rate slightly lower than 96.5%. In weekly-CT2, 
gamma passing rate was higher but there was more than 2% variation in V95%PTV. On 
the contrary weekly-CT3 even with low PVnorm does not follow any of the defined 
criteria which make it a special case to root analyze the possible reasons.   
 
Figure 5.18: Bar graph for Patient F. All the weekly-CTs represent lower PVnorm correspond and only 
weekly-CT1 with high variation in V95% PTV, gamma passing rate was high for all weekly-CTs 
 
Figure 5.19: The registration images of patient F for all the weekly-CTs. The worst case was weekly-CT1 
and the remaining were better than weekly-CT1 (red= planning-CT, aqua= weekly-CT) 
After the detailed analysis it turned out that this patient had a surgery after 
having a planning-CT which resulted in worst case for the registration (it should be 
noted that these results are from image registration, does not mean these errors were 
the same during the actual treatment). As shown in figure 5.19, the image registration 
was worst for the weekly-CT1 and gradually got slightly better for weekly-CT2 and 
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CT3. For this patient, surgery was not the only problem but extreme positioning errors 
affected the registration results simultaneously.  
As described above, the reason for having low quality image registration, 
similar applies to WEPL maps which require image registration of planning and 
weekly-CTs. It was observed from figure 5.20 the peaks representing majority of the 
variations laid outside the defined minimum range of tissue variation ±3 mm for field 1 
of all the weekly-CTs. On the other hand figure 5.21 showed peaks of variations within 
the range of ±3 mm for field 2 thus the combine effect from both the field resulted in 
low PVnorm. 
 
Figure 5.20: Histogram of accWEPL difference map for field 1; all weekly-CT’s of Patient F 
 
Figure 5.21: Histogram of accWEPL difference map for field 2; all weekly-CTs of Patient F 
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Figure 5.22: Point analysis for Patient F. (a) For Weekly-CT1, field 2. (b) For weekly-CT3, field 2. The 
bowel changes effect from planning-CT (a1) and weekly-CT (a2) can be observed in (a3) CT value (HU) 
and also in (a4) accWEPL difference map. The current value is the accWEPL value for that specific beam 
indicated by red arrow. The movement of surgical clip in planning-CT (b1) and weekly CT (b2) can be 
observed and the resulting effect in (b3) CT value (HU) and (b4) accWEPL difference map. Again one 
can compare the area of the difference map filled with variations, for weekly-CT1 a lot of points with 
variations but in weekly-CT3 most of the area is black which represents points within ±3mm. 
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After point analysis on all the weekly-CTs shown in figure 5.22, it was proven 
that major density variations were due to positioning error, surgical clip movement and 
amount of lung in the beam’s path. Since this patient had small target volume the 
aforementioned effects were prominent for this patient although changes in bowel 
movement were not dominant as seen in previous patient example.  
On the whole, weekly-CT1 demonstrated V95%PTV variation up to 7% and 
gamma passing rate 96.4% with PVnorm lower than 56%, these result were in 
accordance with the action level criteria. However weekly-CT2 and CT3 represents as 
those cases which are difficult to decide by relying only on one parameter thus would 
require further investigation.  
5.5 Summary 
In this chapter, a strong correlation was found among PTV, gamma passing 
rate and WEPL variation. By analysis of this correlation the criteria was defined for 
PVnorm as tolerance and action level which was justified by the patient examples from 
this study.  
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Chapter 6 
Discussion and Conclusion 
6.1 Discussion 
From the last few years charged particle therapy has become a popular 
treatment option for the pancreatic cancer. Many radiation oncologists opt for it to 
deliver an effective and precise dose to pancreatic tumor surrounded by dose limiting 
critical structures such as bowel, liver, kidney and spinal cord. There are several 
studies which explain the improved results of charged particle therapy over photons 
IMRT. The special concern is usually given to reduce the dose to OARs that is 
certainly achieved by charged particle therapy due to their finite range. In one of the 
comparative studies Zurlo [43] discussed about proton therapy over photon therapy 
for pancreatic cancer, authors examined the treatment dosimetry plans and found that 
proton therapy has the potential to achieve superior absorbed dose distributions 
compared with photon therapy.  
Further attention was given to optimize the treatment plans by achieving 
suitable beam geometry. As Dreher et al [44] studied different beam geometries for 
the treatment of pancreatic cancer using raster-scanning technique and suggested 
that 3-field configuration have the best dose distribution, single treatment field is 
robust however 2 oblique posterior fields is most favorable. The result from this study 
has been implemented in HIT facility for the treatment of pancreatic cancer that is why 
in this work the majority of the patients have 2 oblique posterior fields. An additional 
study by Batista [45] was conducted by taking into account the inter and intra-
fractional motion effects on the target coverage using scanned carbon ion beams and 
suggested that 2 oblique posterior treatment fields is a robust beam geometry to 
minimize the dose degradation due to organ motion for the treatment of pancreatic 
cancer.  
Since internal organ motion could largely affect the range of charged particles 
resulting in high dose to OARs, many mitigation techniques have already been 
considered such as respiratory gating and abdominal compression. Although 
abdominal compression has been implemented in HIT facility for liver tumors, for 
pancreatic patients due to the use of posterior beams and in order to avoid radiation 
beam through the couch, the patients are positioned prone which makes impossible 
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the use of abdominal compression. Further improvement was investigated by Richter 
[46] and found that by increasing the treatment beam spot size the dose heterogeneity 
caused by motion could be reduced.  
Adaptive therapy is considered a promising option to overcome the inter-
fractional motion. There are several studies on head and neck tumors which emphasis 
on the need of adaptive particle therapy for example Thomson et al [47] discussed the 
impact of organ motion on oropharynx cancer. The author suggested that protons are 
much sensitive to inter-fractional anatomic changes which could result in clinically 
significant increased delivered doses to several OARs and emphasized on adaptation 
of those changes during the course of treatment. Although, Chen et al [48] suggested 
an adaptive strategy by expanding the dosimetry plan library for a specific patient and 
implementing it depending on the best anatomical match. Authors created offline 
plans on daily CT, starting from first fraction and used those plans for subsequent 
fractions which have similar anatomic changes. This strategy seems difficult to 
implement in daily clinical routine because of the time consumption when creating new 
treatment plans.  
As researchers are consistently proposing new ways of adaptive therapy, 
similarly, the rationale of this thesis was also to develop the criteria which could help 
in treatment plan adaptation by simplest means and clinically applicable to the HIT 
clinical routine. This work investigated motion effect on the WEPL and its correlation 
to the variation of dosimetric parameters. The results were similar to the study from 
Matney [49] where author found no significant correlation of tumor centroid motion 
with change in dose, in section 3.8 the variation of V95%CTV has been discussed and 
found that CTV coverage remained uniformed for most of the patients and this was 
verified by correlating it to PVnorm which showed weak correlation. Further Matney 
outlines the strong correlation of WEPL with change in dose and gamma passing rate 
which is similar to the presented results in section 5.1.2 and 5.1.3. 
From the results of WEPL variation, it was found that surgical clip present 
within the CTV have been one of the cause of variation, for all the patient of this study. 
Its movement was regulated by the tumor motion itself resulting in different position on 
every fraction. Van der Horst performed a study [50] to quantify the inter-fractional 
movement of surgical clip in pancreatic tumors; investigation revealed that there is 10 
mm variation on a daily basis. This result explains the reason for having WEPL 
variation in CTV. 
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Kumagai et al [51] investigated carbon ion beam dose variation due to bowel 
gas movement in pancreatic radiotherapy, however it was done for intra-fractional 
motion. The results from this study suggested that there was variation in target 
conformity (approx 3% for CTV) resulting in dose degradation due to over or 
undershoot of the beam, also excessive dosage found to the OARs. Aforementioned 
effects were also the result of the presented study where large variations were 
observed for V95%PTV (mean variation 2.2%) and V95%CTV (mean variation 1.4%) this 
was justified by corresponding WEPL variations, as explained in section 5.2.1 with an 
example.  
In section 5.2.1, patient F example was explained and it was found that WEPL 
variation is high for the weekly-CTs but V95%PTV of two weekly-CT represented slight 
variation; one of the suggested reasons for such result was the size of the tumor. That 
patient was comparatively younger than other patients included in this study thus the 
size of the CTV was also relatively small. Moreover patient had a surgery as well 
before the treatment. This effect is explained by Zurlo [43] in a study where large 
volumes were investigated for the treatment of pancreatic tumor irradiated with 
protons. One of the results found by the author was that for small tumors or 
postoperative patient target dose conformity was superior to those with unresectable 
or large tumors, however, doses to OARs were still close to the maximum limit 
tolerance defined.  
In the presented work, it was assumed that patients were precisely 
immobilized but the similar patient example which was explained above emphasizes 
on further improvement regarding patient positioning and setup errors. For this case it 
was found that large variation in WEPL was primarily due to extreme error in patient 
positioning however these are possible errors came up after the image registration. 
Despite the fact that prone position is the requirement of robust beam configuration 
explained earlier, it is suggested that body mask would be a considerable option for 
these setups.  
From this work it was found that using WEPL for the assessment of density 
variation on a daily basis is less time consuming which could hardly take 5 minutes for 
calculation which is suitable time duration for making a decision in a practical 
scenario. This was also suggested by Matney et al [49] where they found very less 
computational time for the calculation of WEPL.  
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6.2 Conclusion 
This thesis investigated the impact of inter-fractional motion on dosimetric 
parameters that resulted in major density variation in particle therapy. Similar 
investigation was performed using WEPL as a clinical metric to quantify the resulting 
effect of inter-fractional motion. The study revealed strong correlation of variation in 
dose distribution and WEPL due to density variations. The evaluation of WEPL has 
led in this work to develop the criteria for WEPL which could be used as a tool for the 
physicians to predict the necessity of treatment plan adaptation. Fast calculation of 
WEPL with less hassle is a proven advantage found through this work. However it is a 
small retrospective study with limited statistical power but encourages further efforts 
with higher patient numbers to refine the suggested criteria. Since this thesis only 
considers inter-fractional motion, the work can be improved by taking into account of 
intra-fractional motion.   
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Appendix  
A.1 Dosimetric and WEPL Evaluation Parameters 
Table A.1 (a): Evaluation of dose distribution for all the patients included in this thesis. This 
table includes V95%PTV variation, maximum dose of PTV, Dmin PTV and Dmean PTV. 
Patient CT 
V95%PTV 
Variation (%) 
Max. Dose of 
PTV (GyE) 
PTV Dmin 
(GyE) 
PTV Dmean 
(GyE) 
A 
Plan - 2.05 0.48 1.76 
1 0.31 2.16 0.32 1.76 
2 1.83 2.13 0.14 1.75 
3 0.85 2.24 0.38 1.76 
4 1.83 2.12 0.39 1.76 
5 1.50 2.07 0.10 1.75 
Mean 1.26 2.13 0.30 1.76 
Std dev 0.59 0.07 0.15 0.01 
B 
Plan - 2.10 0.27 1.78 
1 4.75 2.10 0.01 1.73 
2 4.33 2.08 0.01 1.73 
3 6.52 2.09 0.02 1.70 
Mean 5.20 2.09 0.08 1.73 
Std dev 0.94 0.01 0.13 0.03 
C 
Plan - 2.24 0.07 1.67 
1 0.02 2.28 0.11 1.66 
2 0.07 2.26 0.11 1.67 
3 0.00 2.28 0.21 1.67 
Mean 0.03 2.27 0.12 1.67 
Std dev 0.02 0.02 0.06 0.00 
D 
Plan - 2.03 0.43 1.76 
1 0.37 2.11 0.59 1.76 
2 1.25 2.10 0.70 1.75 
3 1.36 2.11 0.63 1.75 
Mean 0.99 2.09 0.59 1.75 
Std dev 0.44 0.04 0.12 0.01 
E 
Plan - 2.11 0.25 1.76 
1 4.78 2.15 0.16 1.75 
2 2.29 2.17 0.40 1.76 
3 1.65 2.19 0.17 1.75 
Mean 2.90 2.15 0.25 1.75 
Std dev 1.35 0.03 0.11 0.01 
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Continuation of table A.1 (a) 
Patient CT 
V95%PTV 
Variation (%) 
Max. Dose of 
PTV (GyE) 
PTV Dmin 
(GyE) 
PTV Dmean 
(GyE) 
F 
Plan - 2.30 1.22 2.00 
1 7.13 2.63 0.94 1.98 
2 2.79 2.40 1.20 2.00 
3 1.51 2.34 1.10 2.02 
Mean 3.81 2.42 1.12 2.00 
Std dev 2.40 0.15 0.13 0.02 
G 
Plan - 2.63 0.97 1.78 
1 0.46 2.63 0.81 1.78 
2 0.26 2.17 0.33 1.76 
3 0.36 2.64 0.84 1.77 
Mean 0.36 2.52 0.73 1.77 
Std dev 0.08 0.23 0.28 0.01 
H 
Plan - 2.19 0.91 1.78 
1 0.57 2.19 0.79 1.78 
2 2.52 2.23 0.41 1.78 
3 2.89 2.24 0.90 1.78 
4 1.24 2.24 1.29 1.78 
Mean 1.80 2.22 0.86 1.78 
Std dev 0.92 0.03 0.32 0.00 
I 
Plan - 4.31 2.40 3.80 
1 1.75 4.33 2.28 3.79 
Mean 1.75 4.32 2.34 3.80 
Std dev 0.00 0.01 0.09 0.01 
J 
Plan - 2.10 0.94 1.74 
1 2.65 2.13 0.52 1.73 
2 0.10 2.15 0.57 1.72 
3 2.79 2.22 0.18 1.68 
4 1.17 2.15 0.19 1.71 
5 4.88 2.21 0.04 1.67 
Mean 2.31 2.16 0.41 1.71 
Std dev 1.62 0.05 0.33 0.03 
K 
Plan - 2.12 0.65 1.79 
1 2.43 2.17 0.13 1.78 
2 3.40 2.35 0.15 1.79 
3 0.85 2.32 0.40 1.80 
4 2.55 2.35 0.12 1.79 
5 3.49 2.27 0.29 1.80 
6 3.70 2.34 0.81 1.78 
Mean 2.73 2.28 0.36 1.79 
Std dev 0.96 0.09 0.27 0.01 
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Table A.1 (b): Evaluation of dose distribution and WEPL assessment for all the patients 
included in this thesis. This table includes V95%CTV variation, gamma passing rate and PVnorm 
in the WEPL distal and proximal analysis. 
Patient CT 
V95%CTV 
Variation (%) 
Gamma Passing 
Rate (%) 
Distal 
PVnorm (%) 
Proximal 
PVnorm (%) 
A 
Plan - - - - 
1 1.68 98.6 72.7 71 
2 0.61 97.5 75.5 77 
3 1.75 98.5 79.1 82.5 
4 1.95 98.2 72.2 75.7 
5 0.77 98.7 60.2 59.5 
Mean 1.35 98.2 71.9 73.1 
Std dev 0.55 0.48 6.3 7.7 
B 
Plan - - - - 
1 3.63 96.7 69.3 77 
2 2.71 96.8 51.6 52 
3 4.05 96.5 50.3 50.7 
Mean 3.46 96.6 57 59.9 
Std dev 0.55 0.15 8.6 12.1 
C 
Plan - - - - 
1 0.36 99.3 81.3 90.1 
2 0.92 98.9 73.7 80.4 
3 0.89 98.6 85.7 94.3 
Mean 0.72 98.9 80.2 88.2 
Std dev 0.25 0.35 4.9 5.8 
D 
Plan - - - - 
1 0 99.7 98.1 98.1 
2 0.28 98.8 88.9 89.3 
3 0.47 99.2 79.2 80.3 
Mean 0.25 99.2 88.7 89.2 
Std dev 0.19 0.45 7.7 7.2 
E 
Plan - - - - 
1 1.27 97.5 76.9 74.7 
2 1.1 97.8 66.5 67.4 
3 0.82 98.7 81.7 82.8 
Mean 1.06 98 75 74.9 
Std dev 0.18 0.62 6.3 6.2 
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Continuation of table A.1 (b) 
Patient CT 
V95%CTV 
Variation (%) 
Gamma Passing 
Rate (%) 
Distal 
PVnorm (%) 
Proximal 
PVnorm (%) 
F 
Plan - - - - 
1 2.35 96.4 36.6 30.8 
2 0.18 97 36.9 36.3 
3 1.27 97.8 39 38.1 
Mean 1.26 97 36.6 35 
Std dev 0.88 0.7 1 3.1 
G 
Plan - - - - 
1 0.14 99.5 98.7 98.9 
2 0.79 98.8 74.7 74.7 
3 0.29 99.2 83.1 83 
Mean 0.4 99 85.5 85.5 
Std dev 0.27 0.35 9.9 10 
H 
Plan - - - - 
1 0.03 97.6 70.3 71.5 
2 2.27 97.9 67.6 74.1 
3 2.31 97.5 69.9 70.5 
4 0.36 95.8 72.1 73.4 
Mean 1.24 97 69.9 72.3 
Std dev 1 0.94 1.6 1.4 
I 
Plan - - - - 
1 0.12 96.7 54.4 59 
Mean 0.12 96.7 54.5 59 
Std dev 0 0 0 0 
J 
Plan - - - - 
1 1.7 97.7 71.9 76 
2 0.2 96.7 71.8 72.6 
3 1 92.7 35.1 35.7 
4 0.3 94.7 65.7 69.5 
5 0.5 91.3 23 23.6 
Mean 0.74 94.6 53.5 55.4 
Std dev 0.55 2.6 20.4 21.5 
K 
Plan - - - - 
1 13.6 96.4 71.5 45.8 
2 8.1 96 65.1 67.2 
3 4.8 98.4 74.4 73.1 
4 9.7 96.6 73.7 75.6 
5 4.9 97.2 55.9 51.1 
6 0.4 97.9 59.6 62 
Mean 6.9 97 66.1 62.5 
Std dev 4.1 0.92 7 11.9 
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A.2 OAR analysis 
Table A. 2: Dose evaluation of OARs. This table includes bowel V20%, bowel V80%, kidneys 
V40% and Dmax spinal cord.  
 
Patient CT 
Bowel Kidney V40 (%) 
Spinal Cord 
Dmax (GyE) V20 (%) V80 (%) Right Left 
A 
Plan 19.90 9.10 46.80 41.60 1.45 
1 21.50 12.70 35.80 31.70 1.49 
2 23.60 14.40 36.80 36.60 1.47 
3 24.40 14.70 31.30 39.80 1.47 
4 22.50 13.40 36.40 37.90 1.47 
5 20.10 12.40 37.20 36.30 1.45 
Mean 22.00 12.78 37.38 37.32 1.47 
B 
Plan 12.90 8.90 11.60 9.10 1.47 
1 16.40 10.50 15.40 11.00 1.50 
2 16.90 11.90 17.20 11.30 1.45 
3 24.00 16.90 15.40 11.40 1.47 
Mean 17.55 12.05 14.90 10.70 1.47 
C 
Plan 23.80 10.00 13.00 19.30 1.60 
1 14.40 6.00 15.30 18.40 1.60 
2 14.40 6.30 14.00 18.70 1.69 
3 17.70 7.70 13.00 18.50 1.65 
Mean 17.58 7.50 13.83 18.73 1.64 
D 
Plan 12.60 5.25 17.70 17.70 1.36 
1 3.00 1.17 16.10 20.10 1.33 
2 10.00 5.50 22.50 16.30 1.36 
3 11.80 7.50 10.80 15.20 1.35 
Mean 9.35 4.86 16.78 17.33 1.35 
E 
Plan 18.20 8.25 18.30 17.90 1.51 
1 15.20 6.60 21.40 21.90 1.47 
2 21.00 11.60 14.50 23.70 1.49 
3 20.80 12.00 15.60 27.40 1.49 
Mean 18.80 9.61 17.45 22.73 1.49 
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Continuation of table A.2 
Patient CT 
Bowel Kidney V40 (%) 
Spinal Cord 
Dmax (GyE) V20 (%) V80 (%) Right Left 
F 
Plan 9.30 1.67 17.60 4.10 1.68 
1 10.40 1.90 18.60 3.98 1.64 
2 9.80 1.80 17.70 4.00 1.66 
3 10.00 1.50 17.70 4.00 1.68 
Mean 9.88 1.72 17.90 4.02 1.67 
G 
Plan 11.90 3.43 31.00 28.60 1.56 
1 6.80 1.14 29.70 36.00 1.56 
2 9.70 2.42 24.00 35.30 1.58 
3 12.00 4.80 30.20 40.70 1.54 
Mean 10.10 2.95 28.73 35.15 1.56 
H 
Plan 11.10 3.50 12.20 17.30 1.38 
1 10.50 3.00 14.10 19.60 1.40 
2 11.10 3.50 11.00 14.40 1.38 
3 13.10 4.90 12.70 18.30 1.40 
4 14.00 5.60 13.20 15.50 1.40 
Mean 11.96 4.10 12.64 17.02 1.39 
I 
Plan 12.30 4.79 11.10 0.00 2.70 
1 12.50 4.88 7.95 0.00 2.70 
Mean 12.40 4.84 9.53 0.00 2.70 
J 
Plan 24.30 11.30 13.50 36.00 1.60 
1 23.60 9.80 13.40 36.00 1.60 
2 23.00 9.70 14.00 38.00 1.60 
3 22.70 8.00 14.20 40.00 1.60 
4 22.40 8.50 13.60 39.00 1.60 
5 21.60 7.30 14.50 40.00 1.60 
Mean 22.93 9.10 13.87 38.17 1.60 
K 
Plan 23.00 13.70 22.50 20.40 1.36 
1 20.30 11.80 22.80 21.40 1.36 
2 20.70 12.60 22.20 21.80 1.36 
3 21.80 12.90 22.60 20.20 1.36 
4 20.40 12.30 22.50 21.40 1.38 
5 21.20 13.00 22.30 21.90 1.36 
6 22.70 13.40 22.60 20.20 1.33 
Mean 21.44 12.81 22.50 21.04 1.36 
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A.3 Absorbed Dose Distributions 
Figure A. 3: The dose distribution for all the patients included in this study. (Contoured OARs 
and target volumes: grey = spinal cord, lime = left kidney, mustard = right kidney, white = 
bowel, green = CTV, red = PTV) 
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Continuation of figure A.3 
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Continuation of figure A.3 
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